Contract Research

reMYND offers in vivo drug testing in a wide variety of Alzheimer mouse models. Testing includes biochemical analysis (determination of Aβ 40 and Aβ 42 levels in brain and CSF, APP processing blots, ...), neuropathological analysis (immunohistochemistry on β-amyloid, Thioflavin S staining of plaques, quantitation of plaques, microgliosis and astrocytosis staining, microbleedings detection, ...) and behavioral and memory studies (Morris Water Maze, novel Object Recognition Test, Open Field Test, Rotarod, Pole Test, Beam Walk, …). Different ways of compound administration are possible: intravenous, intraperitonial, intracerebroventricular, subcutaneous, intramuscular, intranasal, oral (gavage), infusion via osmotic pumps, intracranial, …

Including the early years at the University of Leuven, we have served clients for over 10 years, providing reMYND with extensive experience in all types of drug application methods for all types of Aβ treatments. In doing so, reMYND has worked for most of the top pharmaco’s and biotechs active in CNS worldwide, with several treatments now in clinical testing. As we are highly specialized, we always have cohorts of aged mice available, allowing short lead times.

In addition, reMYND sells licenses on its proprietary genotoxicity screen, which was developed for its own discovery program, as a superior alternative to other commercially available solutions addressing genotoxicity liabilities of xenobiotics.

Drug Discovery and Development

reMYND focuses entirely on disease-modifying treatments with the aim to decelerate – or even stop – neuronal degeneration. As such, we respond to a clear unmet medical need, as all marketed treatments and the majority of the products under development world-wide only treat symptoms. Clinicians would consider a decrease in disease progression by 25-30% as a major breakthrough. Still, we target a slowdown of disease progression by at least 50%. Our current lead compound in PD even fully inhibits the progression in the relevant animal models.

In discovery, hits are identified through patent protected cell-lines and validated in-vivo in proprietary animal models. reMYND has focused since 2002 on PD (targeting α-synuclein mediated cytotoxicity) and AD (targeting Tau-mediated cytotoxicity). This gives us several years ahead of competition, as the scientific community starts gradually moving from the β-amyloid pathway towards the Tau pathway as a key target against AD. In addition, our platform can be adapted to target virtually any disease associated with protein-misfolding, such as Diabetes, Huntington, and ALS.

Currently, we focus our development work on 2 compounds against PD and 4 against AD in pre-clinical development. We have demonstrated full disease-modifying proof-of-concept for drug candidate ReS9-S7 in PD with no apparent side effects observed, and early efficacy indications for 2 compound families in AD. All compounds represent small chemical entities with a drug-like chemical structure obeying Lipinski rule of 5.